Oxygenta Pharmaceutical
- Market cap
- ₹ 170 Cr.
- P/E
- 16.3x
- 52-week range
- 43 – 71.59
- ROCE
- −34%
- Dividend yield
- 0%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Oxygenta Pharmaceutical Limited is an India-based company engaged in the manufacturing and selling of pharmaceutical, medical and veterinary preparations. It operates in the pharmaceutical segment. The Company also sells the products to its related companies engaged in the manufacture of formulations. Its active pharmaceutical ingredients (API) products include pantoprazole sodium, vildagliptin, telmisartan, lacosamide, and sertraline hydrochloride. The Company’s chemical products include 3-Amino-1-adamantanol, (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile, 2-N-Propyl-4-methyl-6-(1-methyl benzimidazole-2-yl) benzimidazole, Isobutyramide, 4-Aminobenzonitrile, Valeronitrile and others. Its manufacturing facilities are situated at Sadasivapet Mandal, Sangareddy District, Telangana State.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Oxygenta Pharmaceutical against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)16.3 against a typical 34.3: cheaper than most peers (1st = cheapest).41st of 220
- Sales growth+144.5% against a typical +15.6% from a year earlier.13th of 197
- Share price, 3 months−1.7% against a typical −0.5%.106th of 200
- Size₹ 170.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).124th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 9 | 11 | 13 | 14 | 33 | 49 | 15 | 14 | 34 | 50 | 37 |
| Expenses | 15 | 12 | 12 | 14 | 16 | 38 | 51 | 22 | 19 | 38 | 49 | 36 |
| Operating Profit | −2 | −2 | −2 | −2 | −2 | −4 | −2 | −7 | −5 | −4 | 0 | 1 |
| OPM % | −15.1% | −27.1% | −15.4% | −14.1% | −15.5% | −13.1% | −3.4% | −45.1% | −32% | −12% | 0.2% | 1.5% |
| Other Income | −0 | −0 | 0 | 0 | 1 | 0 | −0 | 0 | −0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | −0 | 1 | 1 | 1 | −0 | 1 |
| Profit before tax | −3 | −4 | −3 | −3 | −3 | −5 | −4 | −8 | −6 | −6 | −1 | −3 |
| Tax % | −0.6% | 6.5% | −409.3% | −51.4% | 2.9% | −20.7% | −43.4% | −25% | −23.5% | −23.4% | 32.8% | −15.9% |
| Net Profit | −3 | −4 | 8 | −1 | −3 | −4 | −2 | −6 | −5 | −5 | −2 | −2 |
| EPS in Rs | −0.94 | −1.13 | 2.4 | −0.38 | −0.8 | −1.06 | −0.58 | −1.65 | −1.33 | −1.31 | −0.46 | −0.57 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 25%
- 5 Years
- 17%
- 3 Years
- 54%
- TTM
- 21%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −28%
- TTM
- 8%
- 10 Years
- 19%
- 5 Years
- 18%
- 3 Years
- 23%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Oxygenta Pharmaceutical | ₹ 48.19 | ₹ 170 Cr. | 16.3x | — | — | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 35x | 5.1x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 95.4x | 14.9x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 71.5x | 18.9x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21x | 4.2x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,08,738 Cr. | 125.1x | 21.1x | — | 15% |
Management
- Sai Sudhakar Vankineni
- Chairman of the Board
- Prasad Reddy Battinapatla
- Chief Financial Officer
- Kumkum Bajaj
- Compliance Officer, Company Secretary
- Amireddy Venkatesu Reddy
- Additional Executive Director
- Chandra Mouliswar Reddy Gangavaram
- Executive Director
- Balasubba Reddy Mamilla
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.